News

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

New MLSDT functional vision test tracks advanced retinitis pigmentosa better than acuity, supporting future gene and optogenetic therapy endpoints.

The prospective, multicenter study enrolled 318 patients across 20 US sites.

China clears first mite-targeting drop for Demodex blepharitis, bringing XDEMVY-style relief and new options beyond lid scrubs and tea tree oil.

Their discussion touches upon EyeSustain’s global efforts to reduce waste in ophthalmology, strategies for greener cataract surgery, and collaborations with industry and professional societies to promote sustainability.

DSP-3077 is being evaluated by Sumitomo Pharma in an ongoing phase 1/2 study (NCT06891885), designed to assess safety, tolerability, and preliminary efficacy in patients with RP.

New STAR trial subgroup data show SYD-101 low-dose atropine slows pediatric myopia, especially ages 3–12 and fast progressors, with good tolerability.

Meta-analysis finds refraction change better than axial length thresholds for tracking childhood myopia, urging growth-curve AL monitoring to flag retinal risk.

The merger, originally announced in March 2025, included the ALLY Robotic Cataract Laser Treatment System.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

Ian Pitha, MD, PhD, argues that leveraging large-scale utilization data to identify the highest-impact medications could help the field get ahead of supply disruptions before they reach patients.

Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

Chiesi Global Rare Diseases said the agency declined to approve its application and requested additional information for the proposed treatment of Leber hereditary optic neuropathy.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

About 90% of patients are female with obesity and potential hormonal drivers

AI-powered polarized-light retinal imaging separates Alzheimer’s from ALS/FTLD deposits with 96% accuracy, promising low-cost early diagnosis.

This scenario emphasizes the need to gain an understanding of the role of hearing impairment in vision rehabilitation outcomes, particularly as they relate to functional independence.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity.